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A plea for renin–angiotensin system blockers as first-line
treatment in cases of severe acute hypertension
Sébastien Rubin 1,2, Romain Boulestreau3, Philippe Gosse4 and Christian Combe 1,5
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The management of hypertension as a chronic disease is now
well codified. Over the last 10 years, blockers of the renin–an-
giotensin system (RAS) have become first-line drugs, often
combined with diuretics or calcium channel blockers, particu-
larly in the population of patients with chronic kidney disease
[1]. The management of acute and severe hypertension is much
less clear-cut. Expert recommendations in this area are based
on very low levels of evidence. However, there is a relative con-
sensus on treatment based on intravenous (IV) infusion of anti-
hypertensive therapy in the first days. Labetalol, nicardipine
and urapidil are the most frequently used drugs in this setting.
The aim is to progressively reduce blood pressure (BP) to
140/90 mmHg in the first 2 or 3 days. We believe that these rec-
ommendations result in underuse of RAS blockers [2].
It is necessary to differentiate between a severe initial presen-
tation of chronic hypertension that does not require emergency
treatment, but rapid assessment, and severe hypertension
reflecting an acute disease that requires urgent treatment—
aortic dissection, acute pulmonary oedema and stroke-induced
hypertension should be managed according to the recommen-
dations specific to these pathologies, which we will not discuss
here [3]. All other severe hypertensive states requiring urgent
treatment have in common small-vessel ischaemia: thrombotic
microangiopathy (TMA)-induced hypertension; malignant hy-
pertension, or better called as multiorgan damage hypertension
[4]; diffuse microvascular injury [3]; scleroderma renal crisis
(SRC); haemolytic uraemic syndrome; and thrombotic throm-
bocytopenic purpura. Within the kidneys, all of these condi-
tions result in high renin secretion. Nearly 50 years ago, Bühler
et al. [5] had already reported high renin secretion in cases of
malignant hypertension. This supports the view that malignant
hypertension is a high-renin hypertension secondary to TMA,
triggers of which are unknown and/or probably multiple. Renal
ischaemia-induced renin secretion rapidly produces a vicious
circle that can exacerbate renal lesions and probably contributes
to vascular lesions in other organs [6]. The RAS stimulates the
sympathetic nervous system, which itself stimulates renin
production via B1 renal receptors. Furthermore, pressure-
induced natriuresis further triggers RAS activation.
Being convinced that renal ischaemia and renin activation
are the cornerstone of the pathogenesis of malignant hyperten-
sion and given that previous series reported efficient and safe
results with angiotensin-converting enzyme inhibitors (ACEis)
in malignant hypertension [5], we have focused our research
for >20 years in our centre on the treatment of malignant hy-
pertension using only oral ACEis [7]. Our protocol involves
early initiation of a small dose of an ACEi (for instance, ramipril
1.25 mg), after a saline infusion in cases of hypovolaemia, fol-
lowed by a forced titration (2.5 mg at 6 h, 5 mg at 12 h, 10 mg at
24 h and a maximum of 10 mg twice a day for the second day)
if well tolerated, with a target systolic BP (SBP) of between 140
and 180 mmHg in the first 48 h, with close monitoring of BP
and creatinine levels. When the maximum ramipril dosage is
reached, a calcium channel blocker is added if the SBP is
>140 mmHg. The third drug class added is a thiazide diuretic,
and if necessary, we finally introduce spironolactone at 25 mg.
Beta blockers are introduced or continued if required by a spe-
cific indication (Table 1). Renal function and potassium levels
are monitored daily. In all reports that we have published on
our experience with this protocol, we have been challenged by
reviewers who were not convinced by this strategy [2, 6, 7].
Three main concerns were raised: the risk of acute kidney injury
(AKI); hyperkalaemia; and less effective BP control than with
IV drug use.
Regarding the first two points, learning from the case of SRC
(probably the most typical presentation of TMA-induced hy-
pertension encountered by nephrologists) should convince us
that raised creatinine levels is not the main concern in the
treatment of severe hypertension. When the SBP reaches very
high levels (>230–250 mmHg), patients are at immediate risk
of stroke, cardiac failure and death. If dialysis is necessary, it
should not lead us to discontinue an indispensable treatment to
break the vicious circle described above. Older reports of
patients saved by bilateral nephrectomy before the availability
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of RAS blockers should not be forgotten, albeit obviously com-
ing from another era [8]. For SRC, ACEi use started in the
1980s, resulting in increased 1-year survival from 15% to 75%—
not through better BP control, but mainly because intense acti-
vation of the RAS is very deleterious [9]. In a French cohort of
SRC patients (2012), >50% of the patients required dialysis, of
whom more than half were able to be discharged within 2 years
[10]. Despite the frequent need for dialysis, no nephrologists
would question the use of RAS blockers as first-line treatment
for the management of high BP in these patients. Moreover, se-
vere AKI requiring dialysis and severe hyperkalaemia remain
uncommon. In our series of malignant hypertension (baseline
creatinine: 173 6 165mmol/L; n¼ 153), no patients required di-
alysis during the acute phase, and because of secondary hyperal-
dosteronism with baseline potassium levels being low
(3.5 6 0.6 mmol/L), none of the patients had potassium levels
>6 mmol/L that required ACEi discontinuation during the
acute phase follow-up [7].
Regarding the third concern, oral management is efficient.
In our series, at discharge, the SBP decreased from 211 6 33 to
141 6 15 mmHg (P< 0.001) and we did not observe any cere-
bral haemorrhage during the acute phase. Moreover, the use of
IV therapeutics is not beyond reproach—in the Studying the
Treatment of Acute hyperTension (STAT) study, the IV strat-
egy applied to patients with a hypertensive emergency was asso-
ciated with 5.6% of patients with sudden hypotension requiring
intervention and 33% of patients with recurrent acute hyperten-
sion [11]. These adverse events were reported to be associated
with increased mortality [12].
Last but not the least, using RAS blockers is less expensive
than IV antihypertensive treatment and can be used more easily
in low- and middle-income countries where malignant hyper-
tension occurs more frequently and use of IV therapy is usually
not an option.
We consider it essential to extend the use of RAS blockers as
the first line of treatment in cases of severe hypertension requir-
ing urgent treatment. This is in line with the pathogenesis of
these hypertensions and is evidenced by the effectiveness of our
therapeutic strategy. We need to generalize the lessons learnt
from the management of SRC, so that we use RAS blockers in
acute hypertensive emergencies.
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FIGURE 1: Treatment protocol used in our unit in cases of malig-
nant hypertension. H0: admission, H6 and following numbers: hours
after admission.
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